Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors

1. Vázquez, S.
2. Villanueva, M.J.
3. Fírvida, J.L.
4. Campos, B.
5. Lázaro, M.
6. Huidobro, G.
7. Areses, M.d.C.
8. Fernández, N.
9. Covela, M.
10. Casal, J.